TY - JOUR
T1 - Intravitreal bevacizumab for diabetic macular oedema
T2 - 5-year results of the Pan-American Collaborative Retina Study group
AU - Arevalo, J. Fernando
AU - Lasave, Andres F.
AU - Wu, Lihteh
AU - Acon, Dhariana
AU - Farah, Michel E.
AU - Gallego-Pinazo, Roberto
AU - Alezzandrini, Arturo A.
AU - Fortuna, Veronica
AU - Quiroz-Mercado, Hugo
AU - Salcedo-Villanueva, Guillermo
AU - Maia, Mauricio
AU - Serrano, Martin
AU - Rojas, Sergio
N1 - Publisher Copyright:
© Published by the BMJ Publishing Group Limited.
PY - 2016/12
Y1 - 2016/12
N2 - Background/aims To report the long-term anatomical and functional outcomes of patients with centre-involved diabetic macular oedema (DME) treated with intravitreal bevacizumab (IVB). Methods Retrospective case series. Patients diagnosed with centre-involved DME that were treated with at least one injection of 1.25mg IVB and had a minimum follow-up of 60months. Patients underwent measurement of best-corrected visual acuity (BCVA), ophthalmoscopy, optical coherence tomography and fluorescein angiography at baseline, 6-month, 12-month, 24-month, 36-month, 48-month and 60-month visits. The paired samples t test was used to compare the central macular thickness (CMT) and BCVA with baseline values. Statistical significance was indicated by p<0.05. Results Two hundred and one consecutive patients (296 eyes) were included. The mean number of IVB injections per eye was 8.4±7.1 (range: 1-47 injections). At 5years, the BCVA remained stable at 20/100 (logarithm of the minimum angle of resolution=0.7±0.4). Eighty-six (29%) eyes improved ≥2 lines of BCVA, 129 (43.6%) eyes remained stable and 81 (27.4%) eyes lost ≥2 lines of BCVA at 60months. Mean CMT decreased from 403.5±142.2μm at baseline to 313.7±117.7μm over 5years follow-up (p≤0.0001). Conclusions The early visual gains due to IVB were not maintained 5years after treatment.
AB - Background/aims To report the long-term anatomical and functional outcomes of patients with centre-involved diabetic macular oedema (DME) treated with intravitreal bevacizumab (IVB). Methods Retrospective case series. Patients diagnosed with centre-involved DME that were treated with at least one injection of 1.25mg IVB and had a minimum follow-up of 60months. Patients underwent measurement of best-corrected visual acuity (BCVA), ophthalmoscopy, optical coherence tomography and fluorescein angiography at baseline, 6-month, 12-month, 24-month, 36-month, 48-month and 60-month visits. The paired samples t test was used to compare the central macular thickness (CMT) and BCVA with baseline values. Statistical significance was indicated by p<0.05. Results Two hundred and one consecutive patients (296 eyes) were included. The mean number of IVB injections per eye was 8.4±7.1 (range: 1-47 injections). At 5years, the BCVA remained stable at 20/100 (logarithm of the minimum angle of resolution=0.7±0.4). Eighty-six (29%) eyes improved ≥2 lines of BCVA, 129 (43.6%) eyes remained stable and 81 (27.4%) eyes lost ≥2 lines of BCVA at 60months. Mean CMT decreased from 403.5±142.2μm at baseline to 313.7±117.7μm over 5years follow-up (p≤0.0001). Conclusions The early visual gains due to IVB were not maintained 5years after treatment.
KW - Macula
KW - Neovascularisation
KW - Posterior Chamber
KW - Retina
KW - Treatment Medical
UR - http://www.scopus.com/inward/record.url?scp=84960192562&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960192562&partnerID=8YFLogxK
U2 - 10.1136/bjophthalmol-2015-307950
DO - 10.1136/bjophthalmol-2015-307950
M3 - Article
C2 - 26912377
AN - SCOPUS:84960192562
SN - 0007-1161
VL - 100
SP - 1605
EP - 1610
JO - British Journal of Ophthalmology
JF - British Journal of Ophthalmology
IS - 12
ER -